About Us
Our Team
Platform Technologies
News
Contact

January 1 2015

January 2015: Accelero Biostructures, Inc. is founded with help from the University of California’s QB3 program

San Francisco: January 2015

Accelero Biostructures, Inc. is founded with help from the University of California’s QB3 program

Structure of Liver Receptor Homolog-1 (NR5A2) with PIP3 hormone bound in the ligand binding pocket. Sept. 2016: Accelero Biostructures, Inc. has received non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) Phase I program

Related Posts

July 2020: Accelero Biostructures Partners with Mid-Atlantic BioTherapeutics to develop Pan-Coronavirus Inhibitors; Receives NIH Funding to Support the Research

May 2019: Accelero Biostructures, Inc. has received additional non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) Phase II program

March 2019: Accelero Biostructures, Inc. expedites structure determinations for groundbreaking research expanding the DNA alphabet from 4 to 8 building blocks

Recent Posts

July 2020: Accelero Biostructures Partners with Mid-Atlantic BioTherapeutics to develop Pan-Coronavirus Inhibitors; Receives NIH Funding to Support the Research
Crystal Structure and Activity Studies of the C11 Cysteine Peptidase from Parabacteroides merdae in the Human Gut Microbiome
PNT1 Is a C11 Cysteine Peptidase Essential for Replication of the Trypanosome Kinetoplast.
May 2019: Accelero Biostructures, Inc. has received additional non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) Phase II program
March 2019: Accelero Biostructures, Inc. expedites structure determinations for groundbreaking research expanding the DNA alphabet from 4 to 8 building blocks

Recent Comments

Archives

July 2020
May 2019
September 2016
January 2015

Categories

Media
Publication

© 2016- Accelero Biostructures.
All Rights Reserved.